Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05586971 · ClinicalTrials.gov registry record · Phase 3
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
A Phase 3 study, sponsored by LG Chem.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,202
- Enrollment target
NCT05586971 is a Phase 3 study that has completed, run by LG Chem. The registered enrollment target is 2,202 participants.
The verdict
NCT05586971, a Phase 3 study, has completed, sponsored by LG Chem.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,202 participants
- Enrollment target
Study Summary
The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
Interventions
- DRUG Placebo
- DRUG Allopurinol
- DRUG Tigulixostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,202 participants |
| Start Date | 2023-03-30 |
| Est. Completion | 2025-05-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05586971
The ClinicalTrials.gov registry entry for NCT05586971 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,202 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LG Chem, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05586971 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05586971 about?
NCT05586971 is a clinical study titled "Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients". The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
What is the current status of trial NCT05586971?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,202 participants. The study started on 2023-03-30. Estimated completion is 2025-05-06.
What interventions are being tested in trial NCT05586971?
The interventions under investigation include: Placebo (DRUG), Allopurinol (DRUG), Tigulixostat (DRUG).
Who is sponsoring clinical trial NCT05586971?
This trial is sponsored by LG Chem, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.